Px-102

Px-102

SCHEMBL17087856

O=C(O)c1ccc([C@H]2C[C@H]2c2ccc(OCc3c(-c4c(Cl)cccc4Cl)noc3C3CC3)cc2Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR1H4

The experimentally established mechanism targets of Px-102. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NR1H4 known ✓ Q96RI1 20/20 1.00
FXR2 P51116 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Px-102 SCHEMBL1164533 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL29366746 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL29823470 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL17087855 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL17087854 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL19633868 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL24662891 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL17087850 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL29709582 1.00 NR1H4 (1.00) NR1H4FXR2
Px-102 SCHEMBL12098287 0.95 NR1H4 (0.91) NR1H4FXR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077268-B2 FXR agonists and methods for making and using SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-09-18 US disclosed
US-20180000768-A1 INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-01-04 US disclosed
US-20180000768-A1 INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-01-04 US disclosed
WO-2017078928-A1 FXR AGONISTS AND METHODS FOR MAKING AND USING SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-05-11 WO disclosed
US-20160376279-A1 FXR AGONISTS AND METHODS FOR MAKING AND USING SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-12-29 US disclosed
US-20160376279-A1 FXR AGONISTS AND METHODS FOR MAKING AND USING SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-12-29 US disclosed
WO-2015138986-A1 FXR AGONISTS AND METHODS FOR MAKING AND USING SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180000768-A1 INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS GLP1R, GIPR, FXR1 NR1H4 10/4885FXR2 6/4885
US-10077268-B2 FXR agonists and methods for making and using NR1H4, FXR2, FXR1 NR1H4 1/4885FXR2 2/4885
US-20160376279-A1 FXR AGONISTS AND METHODS FOR MAKING AND USING NR1H4, FXR2, FXR1 NR1H4 1/4885FXR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.